Immunophenotypes and Immune Markers Associated with Acute Promyelocytic Leukemia Prognosis

Table 2

Comparisons of clinical features and clinical outcomes between CD2+ APL and CD2− APL patients.

Group	CD2− APL	CD2+ APL	P value
Case number	89	12
Age (years) (mean ± SD)	33.67±12.88	30.50±9.85	0.414
Gender (M/F)	49/40	8/4	0.446
WBC count before treatment (×10^9/L) (mean ± SD)	15.06±22.49	34.97±57.6	0.028
CD13+ rate (%) (mean ± SD)	71.00±25.23	71.07±27.52	0.992
CD33+ rate (%) (mean ± SD)	83.96±20.33	83.83±19.24	0.984
CD117+ rate (%) (mean ± SD)	12.62±17.42	12.05±16.33	0.556
CD9+ rate (%) (mean ± SD)	73.60±24.26	68.35±28.47	0.705
CD64+ rate (%) (mean ± SD)	52.74±26.96	49.21±31.64	0.915
CD34+ rate (%) (mean ± SD)	3.63±12.45	13.74±16.42	0.006
CD56+ rate (%) (mean ± SD)	2.41±6.89	0.53±0.53	0.621
Induction therapy
ATRA [𝑛 (%)]	18 (20.2)	4 (33.3)
ATRA + chemotherapy [𝑛 (%)]	38 (42.7)	5 (41.7)
ATRA + As3O2 [𝑛 (%)]	6 (6.7)	1 (8.3)
ATRA + As3O2 + chemotherapy [𝑛 (%)]	27 (30.3)	2 (16.7)
DS incidence [𝑛 (%)]	64 (28.0)	3 (25.0)	1.00
Early death [𝑛 (%)]	14 (15.7)	6 (50)	0.016
Hemorrhage [𝑛 (%)]	10 (71.4)	4 (66.7)
Differentiation syndrome [𝑛 (%)]	2 (14.3)	1 (16.7)
Infection [𝑛 (%)]	1 (7.1)	1 (16.7)
Others [𝑛 (%)]	1 (7.1)	0 (0)
CR rate [𝑛 (%)]	72 (91.1)	6 (50)	0.042
5-year OS [𝑛 (%)]	66 (74.2)	5 (41.7)	0.018
5-year relapse rate [𝑛 (%)]	5 (7.8)	1 (8.3)	1.00

CR: clinical response; DS: differentiation syndrome; OS: overall survival; WBC: white blood cell.